Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients

Inclusion Criteria:

• Males/females aged 40 years and over, at the time of signing the informed consent.

• A female patient is eligible to participate if she is of: Non child-bearing potential,where females are post-menopausal, defined as 12 months of spontaneous amenorrhea [inquestionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) >40 milliinternational units per milliliter (MlU/mL) and estradiol < 40 picograms permililiter (pg/mL) (<147 pmol/L) is confirmatory. Peri-menopausal or pre-menopausal,and have a negative pregnancy test as determined by serum or urine human chorionicgonadotropin (hCG) test, confirmed at screening, and then at each subsequent clinicvisit before the CT scanning is conducted.

• BMI within the range 18 - 32 kilogram per meter^2 (kg/m^2) (inclusive).

• Capable of giving written informed consent, which includes compliance with therequirements and restrictions listed in the consent form.

• Patients will have a diagnosis of IPF as determined by a responsible and experiencedRespiratory physician and based on established criteria defined by the AmericanThoracic Society/European Respiratory Society: American Thoracic Society/EuropeanRespiratory Society International Multidisciplinary Consensus Classification of theIdiopathic Interstitial Pneumonias.

• Patient's lung function measurements of Forced vital capacity (FVC) and Diffusingcapacity of the Lung for Carbon Monoxide (DLCO) at screening must fall within thecategory below to be included in this study: FVC >=40 % predicted and DLCO >=30 %predicted.

Exclusion Criteria:

• Patients with a current Idiopathic Pulmonary Fibrosis (IPF) exacerbation.

• Patients with a known underlying cause of pulmonary fibrosis.

• Patients that have both IPF and Chronic obstructive pulmonary disease (COPD) thatrequires therapy with more than an intermittent bronchodilator or a long actingmuscarinic antagonist, or where the Forced Expiratory Volume in One Second (FEV1)/Forced vital capacity (FVC) ratio is <0.65.

• Patients with an upper or lower respiratory tract infection within four weeks of Visit

• Patients with a recognised co-existing respiratory disorder other than usualinterstitial pneumonia (UIP) (e.g. significant COPD, asthma, sarcoid, lung carcinoma)that in the opinion of the investigator would confound the study outcomes.

• Patients with poorly controlled left ventricular heart failure.

• Serious or uncontrolled medical, surgical or psychiatric disease that in the opinionof the investigator would compromise patient safety or confound the study data (e.g.congestive cardiac failure [CCF], asthma, angina, neurological disease, liverdysfunction and blood dyscrasia).

• Patients found to have clinically significant anaemia until adequately treated.

• Patients that have a history of alcohol abuse.

• Patients who are currently taking Pirfenidone for IPF or who have received Pirfenidonewithin the previous 30 days prior to Visit 1.

• Patients with previous exposure to ionising radiation > 5 millieSievert (mSv) in the 3years prior to enrolment (not including ionising radiation used for therapeutic ordiagnostic purposes or for purposes that involve patient benefit).

• Patients who have a history of claustrophobia.

• As a result of the medical history, physical examination or screening investigations,the physician responsible considers the patient unfit for the study.

• The patient is unable or unwilling to perform study assessments and procedurescorrectly.

• The patient has received an investigational drug for IPF within 30 days of the startof the study.

• A requirement for long-term oxygen therapy (LTOT) as defined by the prescription ofoxygen to be used for greater than or equal to 12 hours of therapy per day. Note -short burst oxygen therapy is permitted.

• Patient is kept under regulatory or judicial order in an institution.

• Patient is mentally or legally incapacitated.